Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.
Actively Recruiting
Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of secutrelvir for treating symptomatic nonhospitalized adults and adolescents with COVID-19 who are at high risk of developing severe disease. This phase 3 trial compares secutrelvir to a placebo to better understand its impact on preventing worsening illness and serious outcomes like hospitalization or death. Participants will be randomly assigned to receive either secutrelvir or a placebo. Both treatments are given orally as tablets. The study includes multiple assessments from baseline through 28 days, and safety monitoring continues up to 24 weeks after treatment. The trial is double-blind, so neither participants nor researchers know who receives the active drug or placebo. During the study, participants will be monitored for COVID-19 symptoms, viral levels, and health status through various measures such as symptom resolution times, medically attended visits, hospitalizations, and quality of life questionnaires. Blood samples will be collected on specific days to analyze drug levels and any side effects. The main outcome is to see how many participants experience worsening illness or serious events within 28 days of starting treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a new device called MDT-0123 compared with the autologous iliac bone graft ICBG in patients who need bone fusion using spinal fixation at two levels ALIF or OLIF due to disc degeneration or spinal deformity in the lower spine L2-S1. This study is a prospective, multi-center, randomized trial aiming to stabilize the spine and improve intervertebral support and correction. Participants will receive either the MDT-0123 spine cage combined with the MDT-0123 kit or the MDT-0123 spine cage combined with the iliac bone graft. Treatments involve surgical implantation of these devices for spinal fusion. The trial compares these two approaches to assess their efficacy and safety over time. During the study, participants will be closely monitored through various assessments including imaging scans such as MRI or myelography, evaluations of disc height, general health condition, disability index Oswestry Disability Index, and pain levels in the lower back and legs. The primary outcomes focus on efficacy and safety at 12 months. Bone fusion timing and other secondary measures will also be tracked. Participants will undergo follow-up visits and evaluations during the 12-month period after surgery to monitor progress and measure study outcomes.